Journal of Vascular and Interventional Radiology
Volume 20, Issue 7 , Pages 951-958 , July 2009

Locally Applied Recombinant Plasmin Results in Effective Thrombolysis in a Porcine Model of Arteriovenous Graft Thrombosis

  • Imo E. Hoefer, MD, PhD

      Affiliations

    • Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationAddress correspondence to I.E.H., University Medical Center Utrecht, Experimental Cardiology, G02.523, Heidelberglaan 100, NL-3584 CX Utrecht, The Netherlands
    • ,
  • Erik S.G. Stroes, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Gerard Pasterkamp, MD, PhD

      Affiliations

    • Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Marcel M. Levi, MD, PhD

      Affiliations

    • Department of Internal Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Jim A. Reekers, MD, PhD

      Affiliations

    • Department of Radiology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Hence J.M. Verhagen, MD, PhD

      Affiliations

    • Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Joost C. Meijers, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • John E. Humphries, MD

      Affiliations

    • Department of Drug Development, Biolex Therapeutics, Pittsboro, North Carolina
    • ,
  • Joris I. Rotmans, MD, PhD

      Affiliations

    • Department of Internal Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands

Received 21 May 2008 ,Revised 23 March 2009 ,Accepted 24 March 2009.

References 

  1. Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg. 2003;38:1005–1011
  2. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535
  3. Saran R, Elder SJ, Goodkin DA, et al. Enhanced training in vascular access creation predicts arteriovenous fistula placement and patency in hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study. Ann Surg. 2008;247:885–891
  4. Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int. 1999;55:2078–2090
  5. Shi Y, O'Brien JE, Mannion JD, et al. Remodeling of autologous saphenous vein grafts (The role of perivascular myofibroblasts). Circulation. 1997;95:2684–2693
  6. Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 2001;59:2325–2334
  7. Falk A, Guller J, Nowakowski FS, et al. Reteplase in the treatment of thrombosed hemodialysis grafts. J Vasc Interv Radiol. 2001;12:1257–1262
  8. Falk A, Harbour K. Tenecteplase in the treatment of thrombosed hemodialysis grafts. Cardiovasc Intervent Radiol. 2005;28:472–475
  9. Falk A, Mitty H, Guller J, Teodorescu V, Uribarri J, Vassalotti J. Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator. J Vasc Interv Radiol. 2001;12:305–311
  10. Sofocleous CT, Hinrichs CR, Weiss SH, et al. Alteplase for hemodialysis access graft thrombolysis. J Vasc Interv Radiol. 2002;13:775–784
  11. Valji K, Bookstein JJ, Roberts AC, Oglevie SB, Pittman C, O'Neill MP. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques. AJR Am J Roentgenol. 1995;164:1495–1500
  12. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976;159:545–553
  13. Wiman B, Boman L, Collen D. On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin. Eur J Biochem. 1978;87:143–146
  14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  15. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost. 2004;2:1617–1621
  16. Chen F, Suzuki Y, Nagai N, et al. Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging. Radiology. 2007;244:429–438
  17. Claeys H, Sottrup-Jensen L, Zajdel M, Petersen TE, Magnusson S. Multiple gene duplication in the evolution of plasminogen (Five regions of sequence homology with the two internally homologous structures in prothrombin). FEBS Lett. 1976;61:20–24
  18. Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86:739–745
  19. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2003;101:3002–3007
  20. Komorowicz E, Kolev K, Machovich R. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry. 1998;37:9112–9118
  21. Hunt J, Bromirski J, Novokhatny V. Inhibition of various plasmin species by plasma inhibitors and its effect on clot lysis. J Thromb Haemost. 2006;4:220
  22. Brookhart GL, Lounes KC, Tomalski MD, et al. Recombinant human plasmin produced in lemna minor. J Thromb Haemost. 2007;5(Suppl 2):P-W-400
  23. Sadeghi S, Marder VJ, Stewart D, et al. Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. J Thromb Haemost. 2003;1:2621–2625
  24. Rotmans JI, Velema E, Verhagen HJ, et al. Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine, bilateral, carotid arteriovenous graft model. J Surg Res. 2003;113:161–171
  25. Rotmans JI, Velema E, Verhagen HJ, et al. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004;39:432–439
  26. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis. 2000;30:204–218
  27. Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC. Improved treatment of thrombosed hemodialysis access sites with thrombolysis and angioplasty. Kidney Int. 1994;46:1375–1380
  28. Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?. Trends Pharmacol Sci. 2004;25:72–75
  29. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost. 2003;1:1034–1041
  30. Flight SM, Masci PP, Lavin MF, Gaffney PJ. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator. Blood Coagul Fibrinolysis. 2006;17:417–420
  31. Rohde V, Rohde I, Thiex R, et al. Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation. J Neurosurg. 2002;97:954–962
  32. Underwood MJ, Cooper G, More R, et al. Effect of intraluminal application of tissue-type plasminogen activator on the fibrinolytic activity of experimental vein grafts. Cardiovasc Res. 1995;29:422–427
  33. Landskroner K, Olson N, Jesmok G. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development. J Vasc Interv Radiol. 2005;16:369–377
  34. Houard X, Rouzet F, Touat Z, et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol. 2007;212:20–28
  35. Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123:1577–1582
  36. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s: choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85:1630–1631

 From the SIR 2008 Annual Meeting.

 None of the authors have identified a conflict of interest.

 This work was financially supported by Biolex Therapeutics (Pittsboro, North Carolina). J.E.H. is a paid employee of Biolex Therapeutics. The expanded polytetrafluoroethylene grafts used in the present study were supplied by W.L. Gore and Associates (Flagstaff, Arizona).

PII: S1051-0443(09)00345-5

doi: 10.1016/j.jvir.2009.03.043

Journal of Vascular and Interventional Radiology
Volume 20, Issue 7 , Pages 951-958 , July 2009

Article Tools

* Image Usage & Resolution